

Randomized double-blind cross-over trial.

Patients with active ulcerative colitis (left sided) were randomized to receive 4.5 gr of tranexamic acid /day vs placebo for 3 weeks at the end of 3 weeks they crossed-over.

Patients could continue on their 5ASA or sulphasalazine

Primary endpoints: visible blood in the stools, clinical and endoscopic improvement

Results: N=12

- Blood in the stools was decreased in 50% TRANEXAMIC vs 16.7% placebo, $p < 0.05$.
- No change in number of stools.
- Sigmoidoscopic appearance was improved in both arms although only the change in endoscopic grading in tranexamic arm was significant $p < 0.05$

Conclusion:

Tranexamic acid may have a part to play in the management of selected patients with ulcerative colitis in whom bleeding is difficult to control with orthodox treatment.

TABLE 2. Effects of tranexamic acid therapy on rectal appearance and bleeding. Patients marked with an asterisk* received tranexamic acid first. The blood in stool data are presented as stools with visible blood (upper number) over the total number of stools passed (lower number) in each treatment period

Patient	Sigmoidoscopic grading			Blood in stool	
	Before trial	Tranexamic acid	Placebo	Tranexamic acid	Placebo
1	2	0	1	1/15	7/23
2	3	1	0	0/43	0/40
3	4	4	4	24/63	20/66
4	4	2	4	1/21	8/38
5	4	2	2	15/39	35/38
6*	2	3	3	10/29	37/43
7*	3	1	1	1/45	0/31
8*	3	1	3	26/76	66/71
9	3	2	2	10/131	27/158
10*	3	2	3	18/18	16/16
11*	4	4	4	60/60	63/63
12*	4	3	3	67/67	63/63

